ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "fatigue and interferons"

  • Abstract Number: 2795 • 2015 ACR/ARHP Annual Meeting

    Fatigue in Primary Sjögren’s Syndrome: Clinical, Laboratory, Psychometric and Biological Associations

    Theofanis Karageorgas1, Sofia Fragkioudaki2, Adrianos Nezos3, Dimitris Karaiskos4, Clio Mavragani5 and Haralampos M. Moutsopoulos6, 1Clinical Immunology and Rheumatology, "Attikon" University Hospital of Athens, Athens, Greece, 2Physiology, Medical School of Athens, Department of Physiology, Athens, Greece, 3Physiology, Department of Experimental Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, 4Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, 5Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, 6Department of Pathophysiology, Medical School of Athens, Department of Pathophysiology, Athens, Greece

    Background/Purpose: To identify independent predictors of fatigue in primary Sjogren’s Syndrome (pSS) patients taking into account clinical, laboratory and psychological features and to explore the…
  • Abstract Number: 1799 • 2014 ACR/ARHP Annual Meeting

    Elevated Indoleamine-2,3-Dioxygenase (IDO) Activity and Kynurinene-3-Monooxygenase (KMO) Expression in Interferon Positive Primary Sjogrens Syndrome Patients Is Associated with Increased CD25hiFoxP3+ regulatory Tcells: A Skew Towards Neurotoxicity or an Attempt to Rescue?

    Naomi I Maria1, Cornelia G. van Helden-Meeuwsen1, Zana Brkic1, Sandra M.J. Paulissen1,2, Virgil A. Dalm1, Paul L. van Daele1, P. Martin van Hagen1, Sinead M. Gibney1,3, Andrew Harkin3, Hemmo A. Drexhage1, Erik Lubberts1,2 and Marjan A. Versnel1, 1Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 2Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands, 3Trinity College Institute of Neuroscience, Neuropsychopharmacology, Dublin, Ireland

    Background/Purpose: A role for indoleamine-2,3-dioxygenase (IDO) in suppression of effector T-cell function and promotion of regulatory T-cell (Treg) differentiation has been described. IDO - the…
  • Abstract Number: 885 • 2013 ACR/ARHP Annual Meeting

    Fatigue In SLE Is Associated With Upregulation Of Interferon- Alpha Related Gene Transcripts

    Maureen A. McMahon1, Jennifer M. Grossman2, Bevra H. Hahn3, Lori Sahakian4, Isao Matsuura5, Elaine Lourenco6 and Brian Skaggs6, 1Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, 3Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 4Division of Rheumatology, Department of Medicine,, UCLA David Geffen School of Medicine, Los Angeles, CA, 5UCLA David Geffen School of Medicine, Los Angeles, CA, 6Medicine/Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Fatigue is a major complaint in at least 80% of SLE patients, and is often listed as the most disabling symptom of the disease;…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology